Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
BUSINESS UPDATE - LETTER OF INTENT IN RELATION TO TWO CLASS 2 MODIFIED NEW DRUGS
Regulatory Filings Classification · 85% confidence The document is an announcement on the Hong Kong Stock Exchange of a letter of intent for a potential drug collaboration. It does not contain financial statements or results, nor is it an earnings release, proxy, dividend notice, board change, capital raising, or takeover bid. It is a general corporate/business update announced to comply with listing rules, and thus falls into the fallback category of general regulatory announcements.
2026-06-04 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 92% confidence The document is a monthly return (Form FF301) filed to the Hong Kong Stock Exchange under Listing Chapter 19B, detailing movements in authorized/issued share capital, treasury shares, share options, repurchases, public float confirmations, and related listing-rule confirmations. It is a routine regulatory submission rather than a financial report (e.g., 10-K, IR) or a standalone announcement of financial results or capital raising. It does not fit one of the more specific categories (e.g., CAP, POS) but is clearly a compliance/regulatory disclosure. Therefore it belongs in the generic Regulatory Filings category (RNS).
2026-06-01 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 76% confidence The document is a voluntary business update announcement on product development (approval of Safinamide Mesylate) by the board. It is not an AGM notice, financial report, earnings release, capital change, management changes, or any specialized form. It represents a general regulatory announcement without fitting into other specific categories, so it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a voluntary business update announcement regarding product development (approval of Azilsartan Medoxomil Potassium) filed on HKEX. It contains no financial results, no meeting notices, no dividends, no share transactions, and no substantive report attached. It is a general regulatory announcement and does not fit any specific category, so it defaults to Regulatory Filings (RNS).
2026-05-21 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a voluntary business update announcement by SSY Group Limited regarding product development approvals from China’s NMPA. It does not contain financial statements, governance rules, shareholder votes, management changes, financing details, or dividend information. It is a general regulatory announcement filed with the Hong Kong Stock Exchange, falling into the fallback category.
2026-05-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a ‘Next Day Disclosure Return’ (Form FF305) filed under Hong Kong Stock Exchange listing rules, detailing changes in issued shares, treasury share repurchase and on-market sales. It is not announcing publication of a separate report but is itself the disclosure of share transactions by the issuer. This aligns with the “Transaction in Own Shares” category (POS) for share repurchases/treasury share sales.
2026-05-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.